CrossrefInfokarte
The cost-effectiveness of biosimilar denosumab in postmenopausal osteoporosis: implications of baseline fracture risk and drug price
Osteoporosis International · 2026-10 · 37 (10) · 2629-2639
DOI: 10.1007/s00198-026-08153-9 ↗Abstract
Kein Abstract verfügbar.
EUVIMED